Transarterial chemoembolization outcomes for advanced hepatocellular carcinoma vs sorafenib and best supportive care in a sub-Saharan African cohort

Figure 1 Kaplan-Meier plot of the overall survival for the 71 patients who underwent transarterial chemoembolization as per Barcelona Clinic Liver Cancer stage B, C, and D disease. BCLC: Barcelona Clinic Liver Cancer.

Figure 2 Univariate and multivariate analysis of hazard ratios for patients treated with transarterial chemoembolization using forest plot representation. a: The hazard ratio was calculated by comparing patients in the lowest 10% to those in the highest 90% of the distribution, serving as the reference group; b: The hazard ratio was calculated by comparing patients in the highest 10% to those in the lower 90% of the distribution, serving as the reference group. CI: Confidence interval; HIV: Human immunodeficiency virus; HBV: Hepatitis B virus; HCV: Hepatitis C virus; VL: Viral load; CTP: Child-Turcotte-Pugh; MELD-Na: Model of end-stage liver disease-sodium; BCLC: Barcelona Clinic Liver Cancer; ECOG-PS: Eastern Cooperative Oncology Group Performance Status; PVI: Portal vein infiltration; WBC: White cell count; CEA: Carcinoembryonic antigen; CA19.9: Carbohydrate antigen 19-9; AFP: Alpha-fetoprotein; INR: International normalized ratio; ALT: Alanine transaminase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; GGT: Gamma-glutamyl transferase; C-bilirubin: Conjugated bilirubin; T-bilirubin: Total bilirubin.

Figure 3 The survival rates. A-C: Across all matched patients, in risk-categorized groups, high-risk group and low-risk group with Barcelona Clinic Liver Cancer (BCLC) stage C disease; D-F: Across all matched patients, in risk-categorized groups, high-risk group and low-risk group with BCLC stage D disease. BCLC: Barcelona Clinic Liver Cancer; BSC: Best supportive care; TACE: Transarterial chemoembolization; GGT: Gamma-glutamyl transferase; AST: Aspartate aminotransferase.